Back to top
more

DiaSorin (DSRLF)

(Delayed Data from OTC)

$107.40 USD

107.40
1

0.00 (0.00%)

Updated Apr 24, 2024 03:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New Strong Sell Stocks for January 29th

by Zacks Equity Research

T, DSRLF and HAFC have been added to the Zacks Rank #5 (Strong Sell) List on January 29, 2023.

Urmimala Biswas headshot

5 Soaring MedTech Stocks to Buy for More Growth in 2021

by Urmimala Biswas

We have selected five MedTech growth stocks with further rooms for improvement in 2021.

InMode (INMD) Surges: Stock Moves 10.6% Higher

by Zacks Equity Research

InMode (INMD) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

Agios Gets Orphan Drug Tag for Mitapivat to Treat Thalassemia

by Zacks Equity Research

The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing patients with thalassemia. Stock rises in after-hours trading.

The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin

Tirthankar Chakraborty headshot

Europe Equities Are Hot on Stimulus Optimism: 5 Picks

by Tirthankar Chakraborty

Europe stocks rally on hopes that the European Union will unveil large stimulus package to reduce the economic fallout from the coronavirus pandemic.

QIAGEN Launches QIAstat-Dx Panel in Europe, Widens Suite

by Zacks Equity Research

QIAGEN (QGEN) continues to expand test menu; latest European launch to boost portfolio and top line.

    QIAGEN's FDA Nod for Expanded EGFR Test Use Widens Suite

    by Zacks Equity Research

    QIAGEN (QGEN) continues to expand test menu; latest FDA approval to boost portfolio.